1. Scrip
  2. >>Drug Pricing

BMS ‘Increasingly Confident’ It Can Handle The Impact Of Medicare Pricing For Eliquis

Pharma To Announce IRA-Mandated Final Price Soon

 
• By Mandy Jackson

Bristol’s CEO offered assurances about Medicare negotiations under the IRA as the company delivered better-than-expected second quarter results across new and legacy products.

MUNICH, GERMANY - 5. July 2024: Bristol Myers Squibb logo sign of the biopharmaceutical company.
BMS raised its 2024 revenue guidance based on its Q2 performance • Source: Shutterstock

Now that Bristol Myers Squibb Company has the maximum fair price (MFP) in hand that Medicare intends to pay for Eliquis (apixaban) starting in 2026 under the drug price negotiation authority granted by the Inflation Reduction Act (IRA), CEO Chris Boerner said the company is “increasingly confident in our ability to navigate the impact of IRA on Eliquis.”

Key Takeaways

  • BMS is “increasingly confident” in its ability to manage through pricing for Eliquis under IRA-mandated Medicare negotiations now that the company has seen the price effective 2026.

Boerner said during Bristol’s second quarter earnings call on 26 July that the company will disclose more details about how...

More from Drug Pricing

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Stock Watch: Generics Firms Trapped Between US Tariffs And European Austerity

 
• By Andy Smith

Successive annual reductions in European drug prices following the pandemic are affecting the global sales of generic pharmaceutical companies. Additionally, the imposition of US import tariffs may result in generic drug supply becoming unprofitable.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

More from Scrip